Hematology
American Board of Internal Medicine
AB, Rutgers College
PhD, Bowman Gray School of Medicine
MD, Tulane University
Internship, Internal Medicine
North Carolina Memorial Hospital
Residency, Internal Medicine
North Carolina Memorial Hospital
Residency, Internal Medicine
National Institutes of Health
Fellowship, Hematology
National Institutes of Health
English
Research
Dr. Walsh directs the Hemophilia Program in the Division of Hematology and Medical Oncology at Mount Sinai School of Medicine. His research focuses on gene therapy of blood diseases. Throughout his career he has had a particular interest in Fanconi anemia and his early work in this area culminated in the first clinical trial in which retroviral vectors were used for gene therapy of patients with Fanconi anemia group C. He is also actively developing gene therapies for hemophilia A and B.
Walsh CE. Fetal gene therapy- a perspective. Gene Ther 1999; 6: 1200-01.
Chao HJ, Walsh CE. Canine FIX antigen in Chapel Hill strain hemophilia B canine. Haemostasis and Thrombosis 1999; 82: 1378.
Walsh CE, Yountz M, Simpson DE. Cellular localization of Fanconi anemia group A protein. Bioch Biophys Res Commun 1999; 259: 594-599.
McMahon LW, Walsh CE, Lambert M. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. J Biol Chem 1999; 274: 32904-08.
Gush K, Fu KL, Grompe M, Walsh CE. Phenotypic correction of Fanconi anemia group C knockout mice. Blood 2000; 95: 700-704.
Chao HJ, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000 Mar; 95(5): 1594-1599.
Chao HJ, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2(6): 619-623.
Yamada K, Olsen JC, Rao K, Walsh CE. Functional correction of Fanconi anemia group C hematopoietic cells using lentiviral vectors. Mol Ther 2001; 3: 485-90.
Chao HJ, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood 2001; 97(10): 3311-2.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Walsh during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.